Zhaoke Ophthalmology

Executive Summary

Zhaoke Ophthalmology is a China-based ophthalmic pharmaceutical and medical device company focused on developing innovative therapies for major eye diseases such as dry eye, glaucoma, and retinal disorders. Leveraging a portfolio of small molecules and advanced drug delivery systems, the company aims to address significant unmet medical needs in the rapidly growing Chinese ophthalmology market. Since its founding in 2001 and transition to a public company, Zhaoke has established a commercial presence, though its product portfolio remains relatively nascent compared to global peers. The company's strategy centers on in-house R&D and potential partnerships to accelerate development and market access.

Upcoming Catalysts (preview)

• Q4 2026NMPA approval decision for dry eye disease candidate (e.g., cyclosporine A formulation)70% success
• Q2 2027Phase 3 top-line data readout for glaucoma drug candidate60% success
• Q3 2026Potential licensing or co-development agreement for retinal disease therapy50% success